New rules to bring stem cell, gene therapies under Central licensing net close regulatory gap

New rules have been introduced to regulate stem cell and gene therapies under a centralized licensing system, aiming to close a regulatory gap. The amendment focuses on addressing unproven cures but will not immediately lower costs or improve accessibility of these therapies.